Why the study?
Venous thromboembolism is not rare and increasingly recognized in athletes, but the diagnosis can be elusive and requires guidance on management and return to play.
Provides clinical guidance on managing VTE in athletes, emphasizing a 3-month DOAC regimen and shared decision-making for safe return to play.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to VTE in athletes; leaves open need for prospective data on treatment duration and return to play.
Venous thromboembolism (VTE) is not rare and is becoming more recognized in our athletic population. This diagnosis can be elusive. A provider must have a high clinical suspicion and use pretest probabilities to order the appropriate studies and accurately diagnose a VTE. Treatment using direct oral anticoagulants for 3 months is recommended in most cases. Gradual return to play can be achieved after treatment is complete. Some athletes, however, may require lifelong anticoagulation. Return to collision sports may be possible using a timed dose strategy if long-term anticoagulation is needed. The management of an athlete with a VTE should include an individualized treatment plan and involve shared decision making with the athlete, team physicians, and hematologic specialists.
No takes yet. Share an insight, caveat, or question.
Fred H. Brennan (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: